2023 Q4 Form 10-Q Financial Statement

#000160706224000033 Filed on January 19, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2022 Q4
Revenue $31.64K $31.64K
YoY Change 0.0% -46.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $134.3K $427.4K
YoY Change -68.57% 758.45%
% of Gross Profit
Research & Development $47.53K $95.51K
YoY Change -50.24% -17.44%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $47.53K $95.51K
YoY Change -50.24% -42.28%
Operating Profit -$122.8K -$463.9K
YoY Change -73.53% 335.88%
Interest Expense $17.76K $17.36K
YoY Change 2.33% -99.38%
% of Operating Profit
Other Income/Expense, Net -$227.0K $0.00
YoY Change -100.0%
Pretax Income -$349.8K $1.636M
YoY Change -121.38% -38.16%
Income Tax
% Of Pretax Income
Net Earnings -$349.8K $1.636M
YoY Change -121.38% -38.16%
Net Earnings / Revenue -1105.44% 5169.82%
Basic Earnings Per Share -$0.10 $0.45
Diluted Earnings Per Share -$0.10 $0.43
COMMON SHARES
Basic Shares Outstanding 3.559M shares 5.032B shares
Diluted Shares Outstanding 3.596M shares 3.361M shares

Balance Sheet

Concept 2023 Q4 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $124.5K $40.74K
YoY Change 205.6% -88.47%
Cash & Equivalents $124.5K $40.74K
Short-Term Investments
Other Short-Term Assets $5.000K $19.09K
YoY Change -73.81% -53.77%
Inventory
Prepaid Expenses $14.09K
Receivables $12.30K $131.7K
Other Receivables $0.00 $0.00
Total Short-Term Assets $141.8K $191.5K
YoY Change -25.97% -70.13%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $17.73K $222.6K
YoY Change -92.03% 136.59%
Other Assets
YoY Change
Total Long-Term Assets $17.73K $222.6K
YoY Change -92.03% 136.59%
TOTAL ASSETS
Total Short-Term Assets $141.8K $191.5K
Total Long-Term Assets $17.73K $222.6K
Total Assets $159.5K $414.1K
YoY Change -61.48% -43.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $44.18K $31.04K
YoY Change 42.35% -3.87%
Accrued Expenses $1.663M $1.614M
YoY Change 3.03% -18.26%
Deferred Revenue
YoY Change
Short-Term Debt $50.21K $1.710K
YoY Change 2836.26% -99.88%
Long-Term Debt Due $509.9K $509.9K
YoY Change 0.0% -59.92%
Total Short-Term Liabilities $5.247M $5.299M
YoY Change -0.98% -49.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $154.0K $0.00
YoY Change
Total Long-Term Liabilities $154.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.247M $5.299M
Total Long-Term Liabilities $154.0K $0.00
Total Liabilities $5.401M $5.299M
YoY Change 1.93% -49.49%
SHAREHOLDERS EQUITY
Retained Earnings -$20.10M -$19.27M
YoY Change 4.3%
Common Stock $376.00 $504.8K
YoY Change -99.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.241M -$4.885M
YoY Change
Total Liabilities & Shareholders Equity $159.5K $414.1K
YoY Change -61.48% -43.68%

Cashflow Statement

Concept 2023 Q4 2022 Q4
OPERATING ACTIVITIES
Net Income -$349.8K $1.636M
YoY Change -121.38% -38.16%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$162.3K -$10.46K
YoY Change 1451.52% -96.25%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $165.8K $0.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -$162.3K -$10.46K
Cash From Investing Activities $0.00
Cash From Financing Activities $165.8K $0.00
Net Change In Cash $3.461K -$10.46K
YoY Change -133.08% -97.2%
FREE CASH FLOW
Cash From Operating Activities -$162.3K -$10.46K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001589150
CY2023Q4 RGBP Convertible Notes Payable Related Parties Less Unamortized Discount Noncurrent
ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNoncurrent
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
usd
CY2023Q4 RGBP Increase Decrease In Contributed Capital
IncreaseDecreaseInContributedCapital
usd
CY2023Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q4 RGBP Common Shares Issued For Debt
CommonSharesIssuedForDebt
usd
CY2022Q4 RGBP Common Shares Issued For Debt
CommonSharesIssuedForDebt
usd
CY2023Q4 RGBP Preferred Share Issued For Debt
PreferredShareIssuedForDebt
usd
CY2023Q4 RGBP Cash Paid For Interest
CashPaidForInterest
usd
CY2022Q4 RGBP Cash Paid For Interest
CashPaidForInterest
usd
CY2023Q4 RGBP Common Shares Issued For Interests
CommonSharesIssuedForInterests
usd
CY2023Q4 RGBP Preferred Shares Issued For Interests
PreferredSharesIssuedForInterests
usd
CY2023Q4 dei Document Type
DocumentType
10-Q
CY2023Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 dei Entity File Number
EntityFileNumber
333-191725
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
REGEN BIOPHARMA INC
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5192997
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
4700 Spring Street
CY2023Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
St 304
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
La Mesa
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91942
CY2023Q4 dei City Area Code
CityAreaCode
619
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
722-5505
CY2023Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2023Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3750565 shares
CY2023Q4 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 us-gaap Cash
Cash
124497 usd
CY2023Q3 us-gaap Cash
Cash
121037 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12298 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2023Q3 RGBP Notes Receivable Related Party Current
NotesReceivableRelatedPartyCurrent
0 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
0 usd
CY2023Q4 us-gaap Prepaid Rent
PrepaidRent
5000 usd
CY2023Q3 us-gaap Prepaid Rent
PrepaidRent
10000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
141795 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
131037 usd
CY2023Q4 RGBP Investment Securities Related Party
InvestmentSecuritiesRelatedParty
17733 usd
CY2023Q3 RGBP Investment Securities Related Party
InvestmentSecuritiesRelatedParty
222580 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
17733 usd
CY2023Q3 us-gaap Other Assets
OtherAssets
222580 usd
CY2023Q4 us-gaap Assets
Assets
159528 usd
CY2023Q3 us-gaap Assets
Assets
353617 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
44183 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
29674 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
49210 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
95710 usd
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
4241 usd
CY2023Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
4241 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
360353 usd
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
342588 usd
CY2023Q4 RGBP Accrued Payroll Current
AccruedPayrollCurrent
1256630 usd
CY2023Q3 RGBP Accrued Payroll Current
AccruedPayrollCurrent
1256630 usd
CY2023Q4 RGBP Other Accrued Expenses
OtherAccruedExpenses
41423 usd
CY2023Q3 RGBP Other Accrued Expenses
OtherAccruedExpenses
41423 usd
CY2023Q4 us-gaap Bank Overdrafts
BankOverdrafts
1000 usd
CY2023Q3 us-gaap Bank Overdrafts
BankOverdrafts
1000 usd
CY2023Q4 RGBP Due To Investor
DueToInvestor
20000 usd
CY2023Q3 RGBP Due To Investor
DueToInvestor
20000 usd
CY2023Q4 RGBP Unearned Income
UnearnedIncome
1560091 usd
CY2023Q3 RGBP Unearned Income
UnearnedIncome
1591731 usd
CY2023Q4 RGBP Unearned Income Related Party
UnearnedIncomeRelatedParty
0 usd
CY2023Q3 RGBP Unearned Income Related Party
UnearnedIncomeRelatedParty
15126 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1400000 usd
CY2023Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
1400000 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
499880 usd
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
499880 usd
CY2023Q4 RGBP Convertible Notes Payable Related Parties Less Unamortized Discount
ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount
10000 usd
CY2023Q3 RGBP Convertible Notes Payable Related Parties Less Unamortized Discount
ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount
10000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5247010 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5308003 usd
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
153981 usd
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
149614 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
153981 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
149614 usd
CY2023Q4 us-gaap Liabilities
Liabilities
5400991 usd
CY2023Q3 us-gaap Liabilities
Liabilities
5457617 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5800000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5800000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3750565 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3750565 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3506366 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3506366 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
376 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
352 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
800000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
800000000 shares
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14120412 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13908141 usd
CY2023Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
736326 usd
CY2023Q3 us-gaap Other Additional Capital
OtherAdditionalCapital
736326 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20098623 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19748863 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5241463 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5104000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159528 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
353617 usd
CY2023Q4 us-gaap Revenues
Revenues
31640 usd
CY2022Q4 us-gaap Revenues
Revenues
31640 usd
CY2023Q4 RGBP Revenues Related Party
RevenuesRelatedParty
27425 usd
CY2022Q4 RGBP Revenues Related Party
RevenuesRelatedParty
27425 usd
CY2023Q4 RGBP Total Revenues
TotalRevenues
59065 usd
CY2022Q4 RGBP Total Revenues
TotalRevenues
59065 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47528 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95513 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12419 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8738 usd
CY2023Q4 us-gaap Professional Fees
ProfessionalFees
106900 usd
CY2022Q4 us-gaap Professional Fees
ProfessionalFees
403680 usd
CY2023Q4 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
15000 usd
CY2022Q4 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
15000 usd
CY2023Q4 us-gaap Costs And Expenses
CostsAndExpenses
181846 usd
CY2022Q4 us-gaap Costs And Expenses
CostsAndExpenses
522931 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-122782 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-463867 usd
CY2023Q4 us-gaap Interest Expense
InterestExpense
17764 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
17359 usd
CY2023Q4 RGBP Interest Expense Attributable To Amortization Of Discount
InterestExpenseAttributableToAmortizationOfDiscount
-4367 usd
CY2022Q4 RGBP Interest Expense Attributable To Amortization Of Discount
InterestExpenseAttributableToAmortizationOfDiscount
0 usd
CY2023Q4 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-204847 usd
CY2022Q4 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
0 usd
CY2023Q4 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
CY2022Q4 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2115806 usd
CY2023Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1150 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-226978 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2099597 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-349760 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
1635730 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-349760 usd
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1448439 usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.4500
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.4500
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3596027 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3596027 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3360540 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3360540 shares
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-5104000 usd
CY2023Q4 RGBP Common Shares Issued For Cash
CommonSharesIssuedForCash
22726 usd
CY2023Q4 RGBP Common Shares Issued For Cash1
CommonSharesIssuedForCash1
46091 usd
CY2023Q4 RGBP Common Shares Issued For Cash2
CommonSharesIssuedForCash2
38205 usd
CY2023Q4 RGBP Common Shares Issued For Cash3
CommonSharesIssuedForCash3
32629 usd
CY2023Q4 RGBP Common Shares Issued For Cash4
CommonSharesIssuedForCash4
38101 usd
CY2023Q4 RGBP Common Shares Issued For Cash5
CommonSharesIssuedForCash5
34543 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-349760 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5241463 usd
CY2022Q4 RGBP Preferred Shares Issued For Nonemployee Services
PreferredSharesIssuedForNonemployeeServices
300000 usd
CY2022Q4 RGBP Preferred Shares Issued For Debt
PreferredSharesIssuedForDebt
761500 usd
CY2022Q4 RGBP Preferred Shares Issued For Interest
PreferredSharesIssuedForInterest
380262 usd
CY2022Q4 RGBP Common Shares Issued For Interest
CommonSharesIssuedForInterest
25369 usd
CY2022Q4 RGBP Preferred Shares Issued For Nonemployee Services1
PreferredSharesIssuedForNonemployeeServices1
48372 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
1635730 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4884827 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-349760 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
1635730 usd
CY2022Q4 RGBP Preferred Stock Issued As Compensation
PreferredStockIssuedAsCompensation
-348372 usd
CY2023Q4 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4367 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
14509 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2240 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12298 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-122575 usd
CY2023Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
17765 usd
CY2022Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
17359 usd
CY2023Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5000 usd
CY2022Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-11856 usd
CY2022Q4 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-2115806 usd
CY2023Q4 us-gaap Increase Decrease In Unearned Premiums
IncreaseDecreaseInUnearnedPremiums
-46767 usd
CY2023Q4 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1 pure
CY2022Q4 us-gaap Increase Decrease In Unearned Premiums
IncreaseDecreaseInUnearnedPremiums
-31640 usd
CY2022Q4 RGBP Gain Loss On Forgiveness Of Debt
GainLossOnForgivenessOfDebt
1150 usd
CY2023Q4 RGBP Unrealized Lossgain On Investment Securities
UnrealizedLossgainOnInvestmentSecurities
-204847 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-162336 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10463 usd
CY2023Q4 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-46500 usd
CY2022Q4 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
0 usd
CY2023Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
212297 usd
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
165797 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3460 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10463 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121037 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51204 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124497 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40741 usd
CY2022Q4 RGBP Preferred Share Issued For Debt
PreferredShareIssuedForDebt
761500 usd
CY2022Q4 RGBP Common Shares Issued For Interests
CommonSharesIssuedForInterests
25269 usd
CY2022Q4 RGBP Preferred Shares Issued For Interests
PreferredSharesIssuedForInterests
380262 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0529 pure
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
9.3298 pure
CY2023Q4 us-gaap Advertising Expense
AdvertisingExpense
0 usd
CY2022Q4 us-gaap Advertising Expense
AdvertisingExpense
0 usd
RGBP Net Income Loss Since Inception
NetIncomeLossSinceInception
20098623 usd
CY2023Q3 RGBP Common Stock Equals Percentage
CommonStockEqualsPercentage
0.80 pure
CY2023Q3 RGBP Common Stock Requested Percentage
CommonStockRequestedPercentage
2 pure
CY2023Q3 RGBP Average Daily Traded Value
AverageDailyTradedValue
250000 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5800000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3750565 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3750565 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
800000000 shares

Files In Submission

Name View Source Status
0001607062-24-000033-index-headers.html Edgar Link pending
0001607062-24-000033-index.html Edgar Link pending
0001607062-24-000033.txt Edgar Link pending
0001607062-24-000033-xbrl.zip Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgbp-20231231.xsd Edgar Link pending
rgbp123123form10q.htm Edgar Link pending
Show.js Edgar Link pending
rgbp-20231231_def.xml Edgar Link unprocessable
rgbp-20231231_cal.xml Edgar Link unprocessable
rgbp-20231231_lab.xml Edgar Link unprocessable
rgbp-20231231_pre.xml Edgar Link unprocessable
rgbp123123form10q_htm.xml Edgar Link completed